financing

The company said it will use the proceeds to develop new liquid biopsy tests to predict drug response in cancer patients.

The company, which has raised $320 million to date, will use the new funds to grow operations and expand into new therapeutic areas and geographies.

The company uses genome editing technologies for agricultural and biomedical applications, including therapeutic cell, tissue, and organ generation.

Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.

The Suzhou, China-based company is developing medicines and molecular diagnostics based on its gene editing and delivery technologies.

The firm said it will use the funds to build its IP portfolio, expand its team, and develop an infrastructure for partners to build on its CRISPR platform.

The San Diego-based company is developing a new DNA sequencing platform that relies on so-called Sequencing By Binding technology.

The firm has reached a deal with certain investors for the purchase of units comprising OncoCyte common shares and warrants to purchase shares.